Haematologic malignancies and blood disorders
Incyte Corp. funds research across diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, primary mediastinal large B-cell lymphoma, and other hematologic malignancies, with additional interest in myelofibrosis, myeloproliferative neoplasms, and myelodysplastic and overlap syndromes. Its portfolio also includes studies in autoimmune hemolytic anemia, immune-mediated thrombocytopenia, and anaemia associated with myelofibrosis.
- Diffuse large B-cell lymphoma
- Myelofibrosis
- Autoimmune cytopenias
Research also extends to treatment settings involving relapsed or refractory disease and advanced blood cancers requiring ongoing therapeutic options.
Inflammatory skin disease and immune-mediated dermatology
The sponsor has a strong focus on atopic dermatitis, hidradenitis suppurativa, prurigo nodularis, chronic hand eczema, chronic spontaneous urticaria, and vitiligo, including nonsegmental and genital vitiligo. Its dermatology research also includes chronic cutaneous inflammation and other immune-mediated skin disorders.
- Atopic dermatitis
- Hidradenitis suppurativa
- Vitiligo
These programs reflect sustained interest in conditions marked by itch, skin lesions, and inflammatory dysregulation.
Solid tumors and oncology
Incyte Corp. supports trials in a broad range of advanced solid tumors, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, ovarian cancer, endometrial cancer, cholangiocarcinoma, head and neck squamous cell carcinoma, anal squamous cell carcinoma, and cutaneous squamous cell carcinoma. The portfolio also includes colorectal cancer and other metastatic malignancies.
- Advanced solid tumors
- Squamous cell carcinomas
- Metastatic disease
Additional activity covers tumors with specific molecular features, including KRAS-altered cancers and FGFR2-rearranged disease.
Immune-mediated and transplant-related disorders
The sponsor funds studies in chronic graft-versus-host disease, including post-transplant immune complications, as well as autoimmune thrombocytopenia and other immune dysregulation syndromes. Its research also includes asthma with an inflammatory phenotype and conditions involving persistent immune activation.
- Chronic graft-versus-host disease
- Autoimmune thrombocytopenia
- Inadequately controlled asthma
These trials span both haematology and immunology, with attention to disorders that require long-term control of immune-mediated pathology.
Fibroinflammatory and rare disease research
Incyte Corp. also invests in less common conditions such as fibrodysplasia ossificans progressiva and myeloproliferative neoplasm-associated anaemia, alongside other rare fibroinflammatory and myeloid disorders. This area includes interest in diseases with complex tissue remodelling and aberrant inflammatory signalling.
- Fibrodysplasia ossificans progressiva
- Myeloproliferative neoplasms
- Rare inflammatory disorders
Its research landscape includes conditions where immune, haematologic, and connective tissue pathways intersect.
